
|Articles|March 1, 2001
- Pharmaceutical Executive-03-01-2001
- Volume 0
- Issue 0
Surrounded
Author(s)Wayne Koberstein
}Drug costs continue to rise at an alarming rate. Two major reasons for the increasing costs are introductions of new drugs and direct-to-consumer advertising campaigns that have been effective in marketing expensive name brand drugs.}
Advertisement
Articles in this issue
over 25 years ago
Research: New Horizonsover 25 years ago
Earnings: Tough Times Aheadover 25 years ago
Outbreak: Anthrax Alarmover 25 years ago
Patents: China on the Genome Mapover 25 years ago
Privacy, Pediatrics, and Policyover 25 years ago
Lilly's International Familyover 25 years ago
Update: Punishment and Reprieveover 25 years ago
Shortage: Vaccine Worriesover 25 years ago
Gateway to JapanAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
The New Healthy Aging Imperative and What It Means for Pharma
2
Why ‘Fully Staffed’ Field Teams Still Miss Revenue Targets—and How Pharma Can Fix It
3
EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval
4
Reading Between the Lines: Closing the T1D Misdiagnosis Gap
5




